Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda (Q38877966)

7 September 2017

title

Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda (English)

1 reference

7 September 2017

0 references

anti-retroviral agent

0 references

1 reference

5

David R Bangsberg

1 reference

7 September 2017

1

Judith A Hahn

1 reference

7 September 2017

Marissa Maier

2

1 reference

7 September 2017

Jayne Byakika-Tusiime

series ordinal

3

1 reference

7 September 2017

Jessica H Oyugi

series ordinal

4

1 reference

7 September 2017

publication date

1 June 2007

1 reference

Journal of the International Association of Providers of AIDS Care

7 September 2017

published in

1 reference

7 September 2017

volume

6

1 reference

7 September 2017

issue

2

1 reference

7 September 2017

page(s)

83-86

1 reference

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Development and validation of a self-completed HIV symptom index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109707299356

21 January 2018

Identifiers

DOI

10.1177/1545109707299356

1 reference

7 September 2017

1 reference